newsfeedback@fool.com (Prosper Junior Bakiny)

Trump’s trade policies have rocked broader equities. Though the president has paused much of his tariff agenda, the volatility it has caused left investors at least a bit worried about what will happen next. That’s understandable, but it’s essential to […]

The market’s recent correction looks like a massive drop on a year-to-date chart. However, it will look far less daunting in a decade; that’s what happens over the long run. Bull markets last longer than downturns. This leads to relatively

Apple (AAPL -0.07%) has faced a wave of headwinds this year, including the prospects of higher costs, thanks to President Trump’s tariff policies. The iPhone maker does significant manufacturing abroad, especially in China, the current administration’s favorite tariff target. Though

Warren Buffett is often considered the greatest investor of all time. His views on this topic (and related ones) carry significant weight on Wall Street, with investors and analysts alike often hanging on his every word during Berkshire Hathaway‘s (NYSE:

President Donald Trump’s second term in office has been challenging for investors, at least so far. Trump imposed sweeping tariffs on imports from most countries worldwide. For now, several industries have escaped these trade policies, including pharmaceuticals. However, recent developments

While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant that title regardless of what’s transpired in 2025. Among them are CRISPR Therapeutics (CRSP 0.12%) and Merck (MRK -1.37%),

The recent stock market sell-off is dragging down many corporations, including Snap (SNAP 1.14%), a social media specialist. Though the company ended 2024 with strong momentum, its shares have declined by 18% since January. Still, there are good reasons to

Last year, Viking Therapeutics, a mid-cap biotech, made waves after it reported excellent phase 2 results for an investigational medicine for weight loss, the industry’s hottest and perhaps fastest-growing therapeutic area. Analysts remain bullish on Viking, but another weight loss

It’s hard to argue with the kinds of results Eli Lilly (LLY 1.71%) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares leaving the broader market in the dust.

Everyone wants a piece of the artificial intelligence (AI) market. Since ChatGPT’s release, AI has grabbed countless headlines on Wall Street and helped many companies rise in prominence. There are many options for investors looking to cash in, and no